PMCC PMCC

Search tips
Search criteria

Advanced
Results 1-25 (4874)
 

Clipboard (0)
None

Select a Filter Below

Journals
more »
Year of Publication
more »
1.  Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial 
Sakata, Yasuhiko | Shiba, Nobuyuki | Takahashi, Jun | Miyata, Satoshi | Nochioka, Kotaro | Miura, Masanobu | Takada, Tsuyoshi | Saga, Chiharu | Shinozaki, Tsuyoshi | Sugi, Masafumi | Nakagawa, Makoto | Sekiguchi, Nobuyo | Komaru, Tatsuya | Kato, Atsushi | Fukuchi, Mitsumasa | Nozaki, Eiji | Hiramoto, Tetsuya | Inoue, Kanichi | Goto, Toshikazu | Ohe, Masatoshi | Tamaki, Kenji | Ibayashi, Setsuro | Ishide, Nobumasa | Maruyama, Yukio | Tsuji, Ichiro | Shimokawa, Hiroaki | Shimokawa, H. | Fukuchi, M. | Goto, T. | Hiramoto, T. | Inoue, K. | Kato, A. | Komaru, T. | Ohe, M. | Sekiguchi, N. | Shiba, N. | Shinozaki, T. | Sugi, M. | Tamaki, K. | Hiramoto, T. | Inoue, K. | Kato, A. | Ogata, M. | Sato, S. | Sugi, M. | Ishide, N. | Ibayashi, S. | Maruyama, Y. | Ohno, I. | Tamaki, K. | Ogawa, H. | Kitakaze, M. | Tsuji, I. | Watanabe, T. | Sugiyama, K. | Oyama, S. | Nozaki, E. | Nakamura, A. | Takahashi, T. | Endo, H. | Fukui, S. | Nakajima, S. | Nakagawa, M. | Nozaki, T. | Yagi, T. | Horiguchi, S. | Fushimi, E. | Sugai, Y. | Takeda, S. | Fukahori, K. | Aizawa, K. | Ohe, M. | Tashima, T. | Sakurai, K. | Kobayashi, T. | Goto, T. | Matsui, M. | Tamada, Y. | Yahagi, T. | Fukui, A. | Takahashi, K. | Takahashi, K. | Kikuchi, Y. | Akai, K. | Kanno, H. | Kaneko, J. | Suzuki, S. | Takahashi, K. | Akai, K. | Katayose, D. | Onodera, S. | Hiramoto, T. | Komatsu, S. | Chida, M. | Iwabuchi, K. | Takeuchi, M. | Yahagi, H. | Takahashi, N. | Otsuka, K. | Koseki, Y. | Morita, M. | Shinozaki, T. | Ishizuka, T. | Onoue, N. | Yamaguchi, N. | Fujita, H. | Katoh, A. | Namiuchi, S. | Sugie, T. | Saji, K. | Takii, T. | Sugimura, A. | Ohashi, J. | Fukuchi, M. | Ogata, M. | Tanikawa, T. | Kitamukai, O. | Matsumoto, Y. | Inoue, K. | Koyama, J. | Tomioka, T. | Shioiri, H. | Ito, Y. | Kato, H. | Takahashi, C. | Kawana, A. | Sakata, Y. | Ito, K. | Nakayama, M. | Fukuda, K. | Takahashi, J. | Miyata, S. | Sugimura, K. | Sato, K. | Matsumoto, Y. | Nakano, M. | Shiroto, T. | Tsuburaya, R. | Nochioka, K. | Yamamoto, H. | Aoki, T. | Hao, K. | Miura, M. | Kondo, M. | Tatebe, S. | Yamamoto, S. | Suzuki, H. | Nishimiya, K. | Yaoita, N. | Sugi, M. | Yamamoto, Y. | Toda, S. | Minatoya, Y. | Takagi, Y. | Hasebe, Y. | Nihei, T. | Hanawa, K. | Fukuda, K. | Sakata, Y. | Takahashi, J. | Miyata, S. | Nochioka, K. | Miura, M. | Tadaki, S. | Ushigome, R. | Yamauchi, T. | Sato, K. | Tsuji, K. | Onose, T. | Abe, R. | Saga, C. | Suenaga, J. | Yamada, Y. | Kimura, J. | Ogino, H. | Oikawa, I. | Watanabe, S. | Saga, M. | Washio, M. | Nagasawa, K. | Nagasawa, S. | Kotaka, S. | Komatsu, W. | Hashimoto, R. | Ikeno, Y. | Suzuki, T. | Hamada, H.
European Heart Journal  2015;36(15):915-923.
We examined whether an additive treatment with an angiotensin receptor blocker, olmesartan, reduces the mortality and morbidity in hypertensive patients with chronic heart failure (CHF) treated with angiotensin-converting enzyme (ACE) inhibitors, β-blockers, or both. In this prospective, randomized, open-label, blinded endpoint study, a total of 1147 hypertensive patients with symptomatic CHF (mean age 66 years, 75% male) were randomized to the addition of olmesartan (n = 578) to baseline therapy vs. control (n = 569). The primary endpoint was a composite of all-cause death, non-fatal acute myocardial infarction, non-fatal stroke, and hospitalization for worsening heart failure. During a median follow-up of 4.4 years, the primary endpoint occurred in 192 patients (33.2%) in the olmesartan group and in 166 patients (29.2%) in the control group [hazard ratio (HR) 1.18; 95% confidence interval (CI), 0.96–1.46, P = 0.112], while renal dysfunction developed more frequently in the olmesartan group (16.8 vs. 10.7%, HR 1.64; 95% CI 1.19–2.26, P = 0.003). Subgroup analysis revealed that addition of olmesartan to combination of ACE inhibitors and β-blockers was associated with increased incidence of the primary endpoint (38.1 vs. 28.2%, HR 1.47; 95% CI 1.11–1.95, P = 0.006), all-cause death (19.4 vs. 13.5%, HR 1.50; 95% CI 1.01–2.23, P = 0.046), and renal dysfunction (21.1 vs. 12.5%, HR 1.85; 95% CI 1.24–2.76, P = 0.003). Additive use of olmesartan did not improve clinical outcomes but worsened renal function in hypertensive CHF patients treated with evidence-based medications. Particularly, the triple combination therapy with olmesartan, ACE inhibitors and β-blockers was associated with increased adverse cardiac events. This study is registered at clinicaltrials.gov-NCT00417222.
doi:10.1093/eurheartj/ehu504
PMCID: PMC4466154  PMID: 25637937
Heart failure; Hypertension; Angiotensin II receptor blocker; Olmesartan
2.  Homozygous inactivation of CHEK2 is linked to a familial case of multiple primary lung cancer with accompanying cancers in other organs 
In clinical practice, there are a number of cancer patients with clear family histories, but the patients lack mutations in known familial cancer syndrome genes. Recent advances in genomic technologies have enhanced the possibility of identifying causative genes in such cases. Two siblings, an elder sister and a younger brother, were found to have multiple primary lung cancers at the age of 60. The former subsequently developed breast cancer and had a history of uterine myoma. The latter had initially developed prostate cancer at the age of 59 and had a history of colon cancer. Single-nucleotide polymorphism (SNP) genotyping revealed that ∼10% of the genomes were homozygous in both patients. Exome sequencing revealed nonsynonymous mutations in five genes in the runs of homozygosity: CHEK2, FCGRT, INPP5J, MYO18B, and SFI1. Evolutionary conservation of primary protein structures suggested the functional importance of the CHEK2 mutation, p.R474C. This mutation altered the tertiary structure of CHK2 by disrupting the salt bridge between p.R474 and p.E394. No such structural changes were observed with the other mutated genes. Subsequent cell-based transfection analysis revealed that CHK2 p.R474C was unstable and scarcely activated. We concluded that the homozygous CHEK2 variant was contributory in this case of familial cancer. Although homozygous inactivation of CHEK2 in mice led to cancers in multiple organs, accumulation of additional human cases is needed to establish its pathogenic role in humans.
doi:10.1101/mcs.a001032
PMCID: PMC5111006  PMID: 27900359
neoplasm of the lung
3.  Impact of Blood Pressure Control on Thromboembolism and Major Hemorrhage in Patients With Nonvalvular Atrial Fibrillation: A Subanalysis of the J‐RHYTHM Registry 
Kodani, Eitaro | Atarashi, Hirotsugu | Inoue, Hiroshi | Okumura, Ken | Yamashita, Takeshi | Otsuka, Toshiaki | Tomita, Hirofumi | Origasa, Hideki | Sakurai, M. | Kawamura, Y. | Kubota, I. | Kaneko, Y. | Matsumoto, K. | Ogawa, S. | Aizawa, Y. | Kodama, I. | Watanabe, E. | Koretsune, Y. | Okuyama, Y. | Shimizu, A. | Igawa, O. | Bando, S. | Fukatani, M. | Saikawa, T. | Chishaki, A. | Kato, N. | Kanda, K. | Kato, J. | Obata, H. | Aoki, M. | Honda, H. | Konta, Y. | Hatayama, T. | Abe, Y. | Terata, K. | Yagi, T. | Ishida, A. | Komatsu, T. | Tachibana, H. | Suzuki, H. | Kamiyama, Y. | Watanabe, T. | Oguma, M. | Itoh, M. | Hirono, O. | Tsunoda, Y. | Ikeda, K. | Kanaya, T. | Sakurai, K. | Sukekawa, H. | Nakada, S. | Itoh, T. | Tange, S. | Manita, M. | Ohta, M. | Eguma, H. | Kato, R. | Endo, Y. | Ogino, T. | Yamazaki, M. | Kanki, H. | Uchida, M. | Miyanaga, S. | Shibayama, K. | Toratani, N. | Kojima, T. | Ichikawa, M. | Saito, M. | Umeda, Y. | Sawanobori, T. | Sohara, H. | Okubo, S. | Okubo, T. | Tokunaga, T. | Kuboyama, O. | Ito, H. | Kitahara, Y. | Sagara, K. | Satoh, T. | Sugi, K. | Kobayashi, Y. | Higashi, Y. | Katoh, T. | Hirayama, Y. | Matsumoto, N. | Takano, M. | Ikeda, T. | Yusu, S. | Niwano, S. | Nakazato, Y. | Kawano, Y. | Sumiyoshi, M. | Hagiwara, N. | Murasaki, K. | Mitamura, H. | Nakagawa, S. | Okishige, K. | Azegami, K. | Aoyagi, H. | Sugiyama, K. | Nishizaki, M. | Yamawake, N. | Watanabe, I. | Ohkubo, K. | Sakurada, H. | Fukamizu, S. | Suzuki, M. | Nagahori, W. | Nakamura, T. | Murakawa, Y. | Hayami, N. | Yoshioka, K. | Amino, M. | Hirao, K. | Yagishita, A. | Ajiki, K. | Fujiu, K. | Imai, Y. | Yamashina, A. | Ishiyama, T. | Sakabe, M. | Nishida, K. | Asanoi, H. | Ueno, H. | Lee, J. D. | Mitsuke, Y. | Furushima, H. | Ebe, K. | Tagawa, M. | Sato, M. | Morikawa, M. | Yamashiro, K. | Takami, K. | Ozawa, T. | Watarai, M. | Yamauchi, M. | Kamiya, H. | Hirayama, H. | Yoshida, Y. | Murohara, T. | Inden, Y. | Osanai, H. | Ohte, N. | Goto, T. | Morishima, I. | Yamamoto, T. | Fujii, E. | Senga, M. | Hayashi, H. | Urushida, T. | Takada, Y. | Tsuboi, N. | Noda, T. | Hirose, T. | Onodera, T. | Kageyama, S. | Osaka, T. | Tomita, T. | Shimada, K. | Nomura, M. | Izawa, H. | Sugiura, A. | Arakawa, T. | Kimura, K. | Mine, T. | Makita, T. | Mizuno, H. | Kobori, A. | Haruna, T. | Takagi, M. | Tanaka, N. | Shimizu, H. | Kurita, T. | Motoki, K. | Takeda, N. | Kijima, Y. | Ito, M. | Nakata, A. | Ueda, Y. | Hirata, A. | Kamakura, S. | Satomi, K. | Yamada, Y. | Yoshiga, Y. | Ogawa, H. | Kimura, M. | Hayano, T. | Kinbara, T. | Tatsuno, H. | Harada, M. | Kusano, K. F. | Adachi, M. | Yano, A. | Sawaguchi, M. | Yamasaki, J. | Matsuura, T. | Tanaka, Y. | Moritani, H. | Maki, T. | Okada, S. | Takechi, M. | Hamada, T. | Nishikado, A. | Takagi, Y. | Matsumoto, I. | Soeki, T. | Doi, Y. | Okawa, M. | Seo, H. | Kitamura, S. | Yamamoto, K. | Akizawa, M. | Kaname, N. | Ando, S. | Narita, S. | Inou, T. | Fukuizumi, Y. | Saku, K. | Ogawa, M. | Urabe, Y. | Ikeuchi, M. | Harada, S. | Yamabe, H. | Imamura, Y. | Yamanouchi, Y. | Sadamatsu, K. | Yoshida, K. | Kubota, T. | Takahashi, N. | Makino, N. | Higuchi, Y. | Ooie, T. | Iwao, T. | Kitamura, K. | Imamura, T. | Maemura, K. | Komiya, N. | Hayano, M. | Yoshida, H. | Kumagai, K.
Background
To clarify the influence of hypertension and blood pressure (BP) control on thromboembolism and major hemorrhage in patients with nonvalvular atrial fibrillation, a post hoc analysis of the J‐RHYTHM Registry was performed.
Methods and Results
A consecutive series of outpatients with atrial fibrillation was enrolled from 158 institutions. Of 7937 patients, 7406 with nonvalvular atrial fibrillation (70.8% men, 69.8±10.0 years) were followed for 2 years or until an event occurred. Hypertension was defined as a systolic BP ≥140 mm Hg, a diastolic BP ≥90 mm Hg, a history of hypertension, and/or antihypertensive drug use. Hypertension was an independent risk factor for major hemorrhage (hazard ratio 1.52, 95% CI 1.05–2.21, P=0.027) but not for thromboembolism (hazard ratio 1.05, 95% CI 0.73–1.52, P=0.787). When patients were divided into quartiles according to their systolic BP at the time closest to the event or at the end of follow‐up (Q1, <114; Q2, 114–125; Q3, 126–135; and Q4, ≥136 mm Hg), odds ratios for both events were significantly higher in Q4 than in Q1 (thromboembolism, odds ratio 2.88, 95% CI 1.75–4.74, P<0.001; major hemorrhage, odds ratio 1.61, 95% CI 1.02–2.53, P=0.041) after adjustment for components of CHA 2 DS 2‐VASc score, warfarin use, and antiplatelet use. A systolic BP of ≥136 mm Hg was an independent risk factor for thromboembolism and major hemorrhage.
Conclusions
BP control appears to be more important than a history of hypertension and baseline BP values at preventing thromboembolism and major hemorrhage in patients with nonvalvular atrial fibrillation.
Clinical Trial Registration
URL: http://www.umin.ac.jp/ctr. Unique identifier: UMIN000001569.
doi:10.1161/JAHA.116.004075
PMCID: PMC5079049  PMID: 27620886
anticoagulation; atrial fibrillation; blood pressure; hypertension; thromboembolism; Atrial Fibrillation; Hypertension; High Blood Pressure; Ischemic Stroke; Intracranial Hemorrhage
4.  Pregabalin- and azithromycin-induced rhabdomyolysis with purpura: An unrecognized interaction: A case report 
Highlights
•Pregabalin and azithromycin therapy is associated with a potentially fatal occurrence of rhabdomyolysis.•We report an extremely rare case of rhabdomyolysis with purpura caused by a drug interaction between pregabalin and azithromycin.•The details of the interaction between azithromycin and the pregabalin are still unknown.
Introduction
Rhabdomyolysis associated with the use of pregabalin or azithromycin has been demonstrated to be a rare but potentially life-threatening adverse event. Here, we report an extremely rare case of rhabdomyolysis with purpura in a patient who had used pregabalin and azithromycin.
Presentation of case
We present the case of a 75-year-old woman with a history of fibromyalgia who was admitted with mild limb weakness and lower abdominal purpura. She was prescribed pregabalin (75 mg, twice daily) for almost 3 months to treat chronic back pain. Her medical history revealed that 3 days before admission, she began experiencing acute bronchitis and was treated with a single dose of azithromycin (500 mg). She had developed rapid onset severe myalgia, mild whole body edema, muscle weakness leading to gait instability, abdominal purpura and tender purpura on the lower extremities. Laboratory values included a white blood cell count of 25,400/mL and a creatinine phosphokinase (CPK) concentration of 1250 IU/L. Based on these findings and the patient’s clinical history, a diagnosis of pregabalin- and azithromycin-induced rhabdomyolysis was made.
Discussion
The long-term use of pregabalin and the initiation azithromycin therapy followed by a rapid onset of rhabdomyolysis is indicative of a drug interaction between pregabalin and azithromycin.
Conclusion
We report an extremely rare case of rhabdomyolysis with purpura caused by a drug interaction between pregabalin and azithromycin. However, the mechanisms of the interactions between azithromycin on the pregabalin are still unknown.
doi:10.1016/j.ijscr.2016.07.007
PMCID: PMC4983139  PMID: 27521491
Pregabalin; Azithromycin; Rhabdomyolysis; Purpura; Adverse reaction; Drug interaction
5.  Imatinib use immediately before stem cell transplantation in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results from Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Study Ph+ALL04 
Cancer Medicine  2015;4(5):682-689.
Incorporation of imatinib into chemotherapeutic regimens has improved the prognosis of children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). We investigated a role of imatinib immediately before hematopoietic stem cell transplantation (HSCT). Children with Ph+ALL were enrolled on JPLSG Ph+ALL 04 Study within 1 week of initiation of treatment for ALL. Treatment regimen consisted of Induction phase, Consolidation phase, Reinduction phase, 2 weeks of imatinib monotherapy phase, and HSCT phase (Etoposide+CY+TBI conditioning). Minimal residual disease (MRD), the amount of BCR–ABL transcripts, was measured with the real-time PCR method. The study was registered in UMIN-CTR: UMIN ID C000000290. Forty-two patients were registered and 36 patients (86%) achieved complete remission (CR). Eight of 17 patients (47%) who had detectable MRD at the beginning of imatinib monotherapy phase showed disappearance or decrease in MRD after imatinib treatment. Consequently, 26 patients received HSCT in the first CR and all the patients had engraftment and no patients died because of complications of HSCT. The 4-year event-free survival rates and overall survival rates among all the 42 patients were 54.1 ± 7.8% and 78.1 ± 6.5%, respectively. Four of six patients who did achieve CR and three of six who relapsed before HSCT were salvaged with imatinib-containing chemotherapy and subsequently treated with HSCT. The survival rate was excellent in this study although all patients received HSCT. A longer use of imatinib concurrently with chemotherapy should eliminate HSCT in a subset of patients with a rapid clearance of the disease.
doi:10.1002/cam4.383
PMCID: PMC4430261  PMID: 25641907
Ph+ALL; children; imatinib; HSCT; MRD
6.  Pravastatin-induced rhabdomyolysis and purpura fulminans in a patient with chronic renal failure 
Highlights
•Pravastatin monotherapy is associated with the potentially fatal side effect of rhabdomyolysis in a patient with chronic renal failure.•The pathogenesis of purpura fulminans with digital gangrene is unclear and thought to be related to the development of DIC.•We report an extremely rare case of pravastatin-induced rhabdomyolysis and purpura fulminans with DIC in a patient with CRF.•This is the first report of pravastatin monotherapy resulting in rhabdomyolysis of the multifidus muscle and purpura fulminans with DIC.
Introduction
Rhabdomyolysis associated with the use of pravastatin has been demonstrated to be a rare but potentially life-threatening adverse effect of statins. Here, we report a rare case of rhabdomyolysis and purpura fulminans in a patient who had used pravastatin and developed chronic renal failure (CRF) necessitating the initiation of dialysis.
Presentation of case
We present the case of an 86-year-old man with chronic kidney disease (CKD) treated with dialysis who was admitted with back pain. He was prescribed and took pravastatin for almost 3 years to treat hyperlipidemia. He received hemodialysis therapy 7 times prior to presentation. Laboratory values included a serum creatine concentration of 6.6 mg/dl and a creatinine phosphokinase (CPK) concentration of 2350 IU/L. An abdominal computed tomography scan showed swollen muscles with reduced muscle density and air density in the multifidus muscle. Two days after admission, he had large, tender ecchymotic lesions and purpuric progressive skin necrosis over the back, abdomen, and upper and lower extremities. The patient died 6 days after the initial admission due to disseminated intravascular coagulation (DIC). Based on these findings and the clinical history, a diagnosis of pravastatin-induced rhabdomyolysis and purpura fulminans was made.
Discussion
The long-term use of statin therapy and the initiation of dialysis therapy due to ESRD, followed by a rapid onset of rhabdomyolysis within 6 days, is indicative of an elevated statin concentration.
Conclusion
We report an extremely rare case of pravastatin-induced rhabdomyolysis and purpura fulminans with DIC in a patient with CRF.
doi:10.1016/j.ijscr.2015.01.042
PMCID: PMC4353943  PMID: 25644555
Pravastatin; Rhabdomyolysis; Disseminated intravascular coagulation (DIC); Purpura fulminans; Chronic renal failure (CRF); Dialysis
7.  Primary colon cancer with a high serum PIVKA-II level 
Highlights
•Protein induced by vitamin K absence or antagonist II (PIVKA-II) is a newly recognized tumor marker for hepatocellular carcinoma.•It is proposed that PIVKA-II may be useful primarily as a prognostic biomarker, predicting rapid tumor progression and poorer prognosis.•PIVKA-II-producing colon cancer is an extremely rare subtype of colon cancer.
Introduction
Protein induced by vitamin K absence/antagonist-II (PIVKA-II) is an abnormal protein, and several reports have demonstrated the efficacy of PIVKA-II in the diagnosis of hepatocellular carcinoma (HCC). We report an extremely rare case of adenocarcinoma of the colon with a high serum PIVKA-II level.
Presentation of Case
A 95-year-old woman presented with right lower quadrant pain and appetite loss. An abdominal computed tomography scan and ultrasonography showed an ascending colon tumor and multiple metastatic tumors in the liver. The serum level of PIVKA-II was extremely high, 11,900 ng/mL. Colonoscopic examination revealed a tumor accompanied by an ulcer in the ascending colon, which was highly suspicious for malignancy. Multiple biopsies showed well-differentiated adenocarcinoma of the colon, which was evaluated as colon cancer, stage IV. PIVKA-II-productive colon cancer was confirmed. Chemotherapy with TS-1 was administered. The patient died 3 months after initial admission.
Discussion
The expression of PIVKA-II was detected in non-cancer areas, with non-specific expression observed in plasma cells in our case. There might be some possibility that hepatoid differentiation exists in other regions of the colon tumor or in the liver tumor, parenchymal cells or lung metastases, which were composed of PIVKA-II-positive and AFP-negative cells.
Conclusion
To the best of our knowledge, high serum levels of PIVKA-II resulting from colon adenocarcinoma have not been reported previously. We report this rare case together with a review of the literature.
doi:10.1016/j.ijscr.2014.11.072
PMCID: PMC4334642  PMID: 25528035
Colon cancer; Adenocarcinoma; Protein induced by vitamin K absence/antagonist-II (PIVKA-II); Carcinoembryonic antigen (CEA); Carbohydrate antigen 19–9 (CA 19–9)
8.  Primary adenocarcinoma of the stomach in von Recklinghausen's disease with high serum levels of multiple tumor markers: a case report 
Introduction
Gastric tumors in patients affected by neurofibromatosis type 1 are usually carcinoids or stromal tumors, and rarely adenocarcinomas.
Case presentation
We report a case of an adenocarcinoma of the stomach in a 53-year-old Japanese man with neurofibromatosis type 1. An abdominal computed tomography scan and ultrasonography showed tumors in his liver. Gastric fibroscopy revealed a Borrmann type III tumor on his cardia that had spread to his esophagus and was highly suspicious for malignancy. Multiple biopsies showed an adenocarcinoma of the stomach, which was evaluated as gastric cancer, stage IV. Chemotherapy with TS-1 was performed. Our patient died four weeks after initial admission. Histological examination of a liver needle biopsy showed metastatic adenocarcinoma in his liver.
Conclusion
To the best of our knowledge, high serum levels of α-fetoprotein, carcinoembryonic antigen, and carbohydrate antigen 72-4, resulting from gastric adenocarcinoma, have not been reported previously in a patient with neurofibromatosis type 1. We report this rare case along with a review of the literature.
doi:10.1186/1752-1947-5-521
PMCID: PMC3212996  PMID: 22018031
9.  Inhibition of Quorum Sensing in Serratia marcescens AS-1 by Synthetic Analogs of N-Acylhomoserine Lactone▿  
Applied and Environmental Microbiology  2007;73(20):6339-6344.
Quorum sensing is a regulatory system for controlling gene expression in response to increasing cell density. N-Acylhomoserine lactone (AHL) is produced by gram-negative bacteria, which use it as a quorum-sensing signal molecule. Serratia marcescens is a gram-negative opportunistic pathogen which is responsible for an increasing number of serious nosocomial infections. S. marcescens AS-1 produces N-hexanoyl homoserine lactone (C6-HSL) and N-(3-oxohexanoyl) homoserine lactone and regulates prodigiosin production, swarming motility, and biofilm formation by AHL-mediated quorum sensing. We synthesized a series of N-acyl cyclopentylamides with acyl chain lengths ranging from 4 to 12 and estimated their inhibitory effects on prodigiosin production in AS-1. One of these molecules, N-nonanoyl-cyclopentylamide (C9-CPA), had a strong inhibitory effect on prodigiosin production. C9-CPA also inhibited the swarming motility and biofilm formation of AS-1. A competition assay revealed that C9-CPA was able to inhibit quorum sensing at four times the concentration of exogenous C6-HSL and was more effective than the previously reported halogenated furanone. Our results demonstrated that C9-CPA was an effective quorum-sensing inhibitor for S. marcescens AS-1.
doi:10.1128/AEM.00593-07
PMCID: PMC2075062  PMID: 17675425
10.  High Serum Adiponectin Level Is a Risk Factor for Anemia in Japanese Men: A Prospective Observational Study of 1,029 Japanese Subjects 
PLoS ONE  2016;11(12):e0165511.
Erythroid abnormalities including anemia and polycythemia are often observed in the general clinical setting. Because recent studies reported that adiponectin negatively affects hematopoiesis, we performed a prospective observational study to assess the relationship between anemia and adiponectin, as well as other parameters, in 1029 Japanese subjects (477 men and 552 women) 40 years of age and older. Body measurements, blood tests, and nutrition intake studies were performed at baseline, and 5 to 7 years later (follow-up). Hemoglobin (Hb) and hematocrit (Hct) levels in men with high serum adiponectin levels were lower at follow-up than at baseline. Multiple regression analysis showed that age, body mass index, adiponectin, and glutamic-pyruvic transaminase were significantly associated with erythroid-related variables (red blood cells, Hb, and Hct) in both men and women (P <0.05). In a logistic regression analysis, adiponectin, fasting blood glucose, and β-natriuretic peptide were significant risk factors for anemia in men, and blood urea nitrogen and amylase were significant risk factors in women. Physical features and nutrient intake were not risk factors for anemia. Our study demonstrates, both clinically and epidemiologically, that a high serum adiponectin level decreases the amounts of erythroid-related variables and is a risk factor for anemia in Japanese men.
doi:10.1371/journal.pone.0165511
PMCID: PMC5137881  PMID: 27918575
11.  A Segmental Copy Number Loss of the SFMBT1 Gene Is a Genetic Risk for Shunt-Responsive, Idiopathic Normal Pressure Hydrocephalus (iNPH): A Case-Control Study 
PLoS ONE  2016;11(11):e0166615.
Little is known about genetic risk factors for idiopathic normal pressure hydrocephalus (iNPH). We examined whether a copy number loss in intron 2 of the SFMBT1 gene could be a genetic risk for shunt-responsive, definite iNPH. Quantitative and digital PCR analyses revealed that 26.0% of shunt-responsive definite iNPH patients (n = 50) had such a genetic change, as compared with 4.2% of the healthy elderly (n = 191) (OR = 7.94, 95%CI: 2.82–23.79, p = 1.8 x 10−5) and 6.3% of patients with Parkinson’s disease (n = 32) (OR = 5.18, 95%CI: 1.1–50.8, p = 0.038). The present study demonstrates that a copy number loss within intron 2 of the SFMBT1 gene may be a genetic risk factor for shunt-responsive definite iNPH.
doi:10.1371/journal.pone.0166615
PMCID: PMC5115754  PMID: 27861535
12.  Effects of Resistance-Associated NS5A Mutations in Hepatitis C Virus on Viral Production and Susceptibility to Antiviral Reagents 
Scientific Reports  2016;6:34652.
Direct-acting antivirals (DAAs) for hepatitis C virus (HCV) have potent anti-HCV effects but may provoke resistance-associated variants (RAVs). In this study, we assessed the characteristics of these RAVs and explored efficacious anti-HCV reagents using recombinant HCV with NS5A from a genotype 1b strain. We replaced the NS5A of JFH1 with that of Con1 (JFH1/5ACon1) and introduced known NS5A inhibitor resistance mutations (L31M, L31V, L31I and Y93H) individually or in combination. Susceptibilities against anti-HCV reagents were also investigated. RAVs with Y93H exhibited high extracellular core antigen levels and infectivity titers. Variants with any single mutation showed mild to moderate resistance against NS5A inhibitors, whereas variants with double mutations at both L31 and Y93 showed severe resistance. The variants with mutations exhibited similar levels of susceptibility to interferon (IFN)-α, IFN-λ1, IFN-λ3 and Ribavirin. Variants with the Y93H mutation were more sensitive to protease inhibitors compared with JFH1/5ACon1. In conclusion, the in vitro analysis indicated that the Y93H mutation enhanced infectious virus production, suggesting advantages in the propagation of RAVs with this mutation. However, these RAVs were susceptible to protease inhibitors. Thus, a therapeutic regimen that includes these reagents is a promising means to eradicate these RAVs.
doi:10.1038/srep34652
PMCID: PMC5050404  PMID: 27703205
13.  An immuno-wall microdevice exhibits rapid and sensitive detection of IDH1-R132H mutation specific to grade II and III gliomas 
Abstract
World Health Organization grade II and III gliomas most frequently occur in the central nervous system (CNS) in adults. Gliomas are not circumscribed; tumor edges are irregular and consist of tumor cells, normal brain tissue, and hyperplastic reactive glial cells. Therefore, the tumors are not fully resectable, resulting in recurrence, malignant progression, and eventual death. Approximately 69–80% of grade II and III gliomas harbor mutations in the isocitrate dehydrogenase 1 gene (IDH1), of which 83–90% are found to be the IDH1-R132H mutation. Detection of the IDH1-R132H mutation should help in the differential diagnosis of grade II and III gliomas from other types of CNS tumors and help determine the boundary between the tumor and normal brain tissue. In this study, we established a highly sensitive antibody-based device, referred to as the immuno-wall, to detect the IDH1-R132H mutation in gliomas. The immuno-wall causes an immunoreaction in microchannels fabricated using a photo-polymerizing polymer. This microdevice enables the analysis of the IDH1 status with a small sample within 15 min with substantially high sensitivity. Our results suggested that 10% content of the IDH1-R132H mutation in a sample of 0.33 μl volume, with 500 ng protein, or from 500 cells is theoretically sufficient for the analysis. The immuno-wall device will enable the rapid and highly sensitive detection of the IDH1-R132H mutation in routine clinical practice.
doi:10.1080/14686996.2016.1227222
PMCID: PMC5101859  PMID: 27877908
Glioma; isocitrate dehydrogenase 1 mutation; immuno-wall microdevice; rapid diagnosis; precision medicine; 30 Bio-inspired and biomedical materials; 404 Materials informatics / Genomics
14.  S100β-Positive Cells of Mesenchymal Origin Reside in the Anterior Lobe of the Embryonic Pituitary Gland 
PLoS ONE  2016;11(10):e0163981.
The anterior and intermediate lobes of the pituitary gland develop through invagination of the oral ectoderm and as they are endocrine tissues, they participate in the maintenance of vital functions via the synthesis and secretion of numerous hormones. We recently observed that several extrapituitary cells invade the anterior lobe of the developing pituitary gland. This raised the question of the origin(s) of these S100β-positive cells, which are not classic endocrine cells but instead comprise a heterogeneous cell population with plural roles, especially as stem/progenitor cells. To better understand the roles of these S100β-positive cells, we performed immunohistochemical analysis using several markers in S100β/GFP-TG rats, which express GFP in S100β-expressing cells under control of the S100β promoter. GFP-positive cells were present as mesenchymal cells surrounding the developing pituitary gland and at Atwell's recess but were not present in the anterior lobe on embryonic day 15.5. These cells were negative for SOX2, a pituitary stem/progenitor marker, and PRRX1, a mesenchyme and pituitary stem/progenitor marker. However, three days later, GFP-positive and PRRX1-positive (but SOX2-negative) cells were observed in the parenchyma of the anterior lobe. Furthermore, some GFP-positive cells were positive for vimentin, p75, isolectin B4, DESMIN, and Ki67. These data suggest that S100β-positive cells of extrapituitary origin invade the anterior lobe, undergoing proliferation and diverse transformation during pituitary organogenesis.
doi:10.1371/journal.pone.0163981
PMCID: PMC5047643  PMID: 27695124
15.  FBXW7 is involved in the acquisition of the malignant phenotype in epithelial ovarian tumors 
Cancer Science  2016;107(10):1399-1405.
FBXW7 is a ubiquitin ligase that mediates ubiquitylation of oncoproteins, such as c‐Myc, cyclin E, Notch and c‐Jun. FBXW7 is a known tumor‐suppressor gene, and mutations in FBXW7 have been reported in various human malignancies. In this study, we examined the sequences of the FBXW7 and p53 genes in 57 ovarian cancer clinical samples. Interestingly, we found no FBXW7 mutations associated with amino acid changes. We also investigated FBXW7 expression levels in 126 epithelial ovarian tumors. FBXW7 expression was negatively correlated with the malignant potential of ovarian tumors. That is to say, FBXW7 expression levels in ovarian cancer samples were significantly lower than those in borderline and benign tumors (P < 0.01). FBXW7 expression levels in serous carcinoma samples were the lowest among four major histological subtypes. In addition, p53‐mutated ovarian cancer samples showed significantly lower levels of FBXW7 expression compared with p53 wild‐type cancer samples (P < 0.001). DNA methylation arrays and bisulfite PCR sequencing experiments revealed that 5′‐upstream regions of FBXW7 gene in p53‐mutated samples were significantly higher methylated compared with those in p53 wild‐type samples (P < 0.01). This data indicates that p53 mutations might suppress FBXW7 expression through DNA hypermethylation of FBXW7 5′‐upstream regions. Thus, FBXW7 expression was downregulated in ovarian cancers, and was associated with p53 mutations and the DNA methylation status of the 5′‐upstream regions of FBXW7.
doi:10.1111/cas.13026
PMCID: PMC5084658  PMID: 27486687
FBXW7; methylation; mutation; ovarian cancer; p53
16.  Antitumor effect of novel anti‐podoplanin antibody NZ‐12 against malignant pleural mesothelioma in an orthotopic xenograft model 
Cancer Science  2016;107(9):1198-1205.
Podoplanin (aggrus) is highly expressed in several types of cancers, including malignant pleural mesothelioma (MPM). Previously, we developed a rat anti‐human podoplanin mAb, NZ‐1, and a rat–human chimeric anti‐human podoplanin antibody, NZ‐8, derived from NZ‐1, which induced antibody‐dependent cellular cytotoxicity (ADCC) and complement‐dependent cytotoxicity against podoplanin‐positive MPM cell lines. In this study, we showed the antitumor effect of NZ‐1, NZ‐8, and NZ‐12, a novel rat–human chimeric anti‐human podoplanin antibody derived from NZ‐1, in an MPM orthotopic xenograft SCID mouse model. Treatment with NZ‐1 and rat NK (CD161a+) cells inhibited the growth of tumors and the production of pleural effusion in NCI‐H290/PDPN or NCI‐H226 orthotopic xenograft mouse models. NZ‐8 and human natural killer (NK) (CD56+) cells also inhibited tumor growth and pleural effusion in MPM orthotopic xenograft mice. Furthermore, NZ‐12 induced potent ADCC mediated by human MNC, compared with either NZ‐1 or NZ‐8. Antitumor effects were observed following treatment with NZ‐12 and human NK (CD56+) cells in MPM orthotopic xenograft mice. In addition, combined immunotherapy using the ADCC activity of NZ‐12 mediated by human NK (CD56+) cells with pemetrexed, led to enhanced antitumor effects in MPM orthotopic xenograft mice. These results strongly suggest that combination therapy with podoplanin‐targeting immunotherapy using both NZ‐12 and pemetrexed might provide an efficacious therapeutic strategy for the treatment of MPM.
doi:10.1111/cas.12985
PMCID: PMC5021042  PMID: 27294401
antibody‐dependent cellular cytotoxicity; mesothelioma; NZ‐12; orthotopic xenograft model; podoplanin
17.  Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese Adverse Drug Event Report database 
Background
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse reactions associated with fatal disorders. Although many causes of SJS/TEN have been proposed, the time-to-onset for SJS/TEN and the relationship between aging and SJS/TEN are still not clear. Therefore, the aim of this study was to determine the relationship between aging and SJS/TEN using the Japanese Adverse Drug Event Report (JADER) database and analyze the time-to-onset profile of SJS/TEN.
Methods
We analyzed reports of SJS/TEN recorded in the JADER database between 2004 and 2015 using an adjusted reporting odds ratio (ROR). We also used Weibull proportional hazards models for each drug to examine the expression patterns of SJS/TEN. We selected the drugs according to the number of the reports associated with SJS/TEN.
Results
The JADER contained 330,686 reports from April 2004 to April 2015. The adjusted RORs for patients in the 0–19-, 20–39-, 60–79-, and ≥ 80-year-old groups from all data extracted from the JADER database were 1.33 (95 % confidence interval [CI], 1.21–1.45), 1.78 (95 % CI, 1.65–1.93), 0.71 (95 % CI, 0.66–0.75), and 0.72 (95 % CI, 0.66–0.79), respectively. The adjusted ROR tended to be higher in patients aged 0–19 years, particularly in patients using antipyretic analgesics, such as loxoprofen or acetaminophen. More than half of the cases of SJS/TEN onset following administration of loxoprofen and acetaminophen occurred within 4 days of the initiation of treatment. The median times-to-onset were 3 days for loxoprofen and 2 days for acetaminophen. The scale parameter α values of loxoprofen and acetaminophen were 9.44 and 6.17, respectively. The upper 95 % CIs of shape parameter β values for the drugs were all less than 1, with the exceptions of those for carbamazepine, ACE inhibitors, and corticosteroids.
Conclusions
Our results suggested that monitoring of younger patients who frequently use antipyretic analgesics is important. These drugs should be used and monitored within the first 2–3 days of treatment in the Japanese population.
doi:10.1186/s40780-016-0048-5
PMCID: PMC4915172  PMID: 27330825
Stevens-Johnson syndrome; Toxic epidermal necrolysis; Japanese Adverse Drug Event Report
18.  Transcription of follicle-stimulating hormone subunit genes is modulated by porcine LIM homeobox transcription factors, LHX2 and LHX3 
The LIM-homeobox transcription factors LHX2 and LHX3s (LHX3a and LHX3b) are thought to be involved in regulating the pituitary glycoprotein hormone subunit genes Cga and Fshβ. These two factors show considerable differences in their amino acid sequences for DNA binding and protein-protein interactions and in their vital function in pituitary development. Hence, we compared the DNA binding properties and transcriptional activities of Cga and Fshβ between LHX2 and LHX3s. A gel mobility shift assay for approximately 1.1 kb upstream of Cga and 2.0 kb upstream of Fshβ varied in binding profiles between LHX2 and LHX3s. DNase I footprinting revealed DNA binding sites in 8 regions of the Cga promoter for LHX2 and LHX3s with small differences in the binding range and strength. In the Fshβ promoter, 14 binding sites were identified for LHX2 and LHX3, respectively. There were alternative binding sites to either gene in addition to similar differences observed in the Cga promoter. The transcriptional activities of LHX2 and LHX3s according to a reporter assay showed cell-type dependent activity with repression in the pituitary gonadotrope lineage LβT2 cells and stimulation in Chinese hamster ovary lineage CHO cells. Reactivity of LHX2 and LHX3s was observed in all regions, and differences were observed in the 5'-upstream region of Fshβ. However, immunohistochemistry showed that LHX2 resides in a small number of gonadotropes in contrast to LHX3. Thus, LHX3 mainly controls Cga and Fshβ expression.
doi:10.1262/jrd.2015-163
PMCID: PMC4919287  PMID: 26853788
Gene regulation; Glycoprotein hormone; LHX2; LHX3; LIM-homeodomain; Pituitary
19.  Safety and short-term outcomes of endoscopic submucosal dissection for early gastric cancer in elderly patients 
Endoscopy International Open  2016;4(5):E521-E526.
Background and study aims: Endoscopic submucosal dissection (ESD) has become widely accepted as a minimally invasive treatment for early gastric cancer (EGC), and opportunities to use ESD to treat EGC in elderly patients are increasing. The objective of this study was to elucidate the safety and efficacy of ESD in elderly patients.
Patients and methods: Between April 2006 and March 2013, a total of 892 patients with EGC were prospectively recruited to undergo ESD according to definite inclusion criteria. The short-term outcomes and incidence of complications in 345 of these patients who were 75 years of age or older (elderly group) were compared with the short-term outcomes and incidence of complications in the remaining 547 patients (non-elderly group). Factors associated with the occurrence of pneumonia and delirium were also investigated.
Results: The R0 resection rate did not differ between the two groups (96.2 % in the elderly group vs. 96.7 % in the non-elderly group; P = 0.65). The incidence of pneumonia (7.5 % vs. 1.8 %; P < 0.01) and incidence of delirium (10.1 % vs. 1.1 %; P < 0.01) were significantly higher in the elderly group. The incidence of post-ESD bleeding and incidence of perforation were similar in the two groups. No emergency surgery was required, but one patient in the non-elderly group died of aspiration pneumonia. On multivariate analysis, age 75 years or older, cerebrovascular disease, chronic obstructive pulmonary disease, delirium, and remnant stomach or gastric tube were independent risk factors for pneumonia, and age 75 years or older, diabetes, dementia, and pneumonia were independent risk factors for delirium.
Conclusion: ESD for EGC was feasible for elderly patients in good condition. However, pneumonia and delirium may develop more frequently after ESD in elderly patients with co-morbidities.
doi:10.1055/s-0042-102650
PMCID: PMC4874799  PMID: 27227108
20.  Relationship between the efficacy of oral antidiabetic drugs and clinical features in type 2 diabetic patients (JDDM38) 
Abstract
Aims/Introduction
We carried out an observational cohort study to examine the relationship between the efficacy of oral antidiabetic drugs and clinical features in type 2 diabetics.
Materials and Methods
We analyzed the CoDiC® database of the Japan Diabetes Data Management Study Group across 67 institutions in Japan. In a total of 3,698 drug‐naïve patients who were initiated with metformin, dipeptidyl peptidase‐4 inhibitor (DPP‐4i) or sulfonylurea (SU) from 2007 to 2012, we evaluated body mass index (BMI) and hemoglobin A1c (HbA1c). The patients were stratified according to their clinical features, and matched using a propensity score to adjust for baseline factors.
Results
HbA1c was reduced with all drugs, with the largest effect elicited by DPP‐4i and the smallest by SU (P = 0.00). HbA1c increased with SU after 6 months in the patients stratified by an age‐of‐onset of <50 years (P = 0.00). BMI increased with SU in the patients stratified by a BMI of <25 (P = 0.00), and decreased with metformin in the patients with a BMI >25 (P = 0.00). The reduction in HbA1c was larger in patients with HbA1c of ≥8%, compared with that in patients with HbA1c of <8% (P = 0.00). HbA1c during the study period was higher in patients who were added to or swapped with other drug(s), than in patients continued on the original drug (P = 0.00).
Conclusions
The effect on bodyweight and glycemic control differed among metformin, DPP‐4i and SU, and the difference was associated with clinical features.
doi:10.1111/jdi.12430
PMCID: PMC4847894  PMID: 27330726
Oral antidiabetic drug; Propensity score‐matched cohort study; Type 2 diabetes mellitus
21.  Characterization of pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia with kinase fusions in Japan 
Blood Cancer Journal  2016;6(5):e419-.
Recent studies revealed that a substantial proportion of patients with high-risk B-cell precursor acute lymphoblastic leukemia (BCP-ALL) harbor fusions involving tyrosine kinase and cytokine receptors, such as ABL1, PDGFRB, JAK2 and CRLF2, which are targeted by tyrosine kinase inhibitors (TKIs). In the present study, transcriptome analysis or multiplex reverse transcriptase–PCR analysis of 373 BCP-ALL patients without recurrent genetic abnormalities identified 29 patients with kinase fusions. Clinically, male predominance (male/female: 22/7), older age at onset (mean age at onset: 8.8 years) and a high white blood cell count at diagnosis (mean: 94 200/μl) reflected the predominance of National Cancer Institute high-risk (NCI-HR) patients (NCI-standard risk/HR: 8/21). Genetic analysis identified three patients with ABL1 rearrangements, eight with PDGFRB rearrangements, two with JAK2 rearrangements, three with IgH-EPOR and one with NCOR1-LYN. Of the 14 patients with CRLF2 rearrangements, two harbored IgH-EPOR and PDGFRB rearrangements. IKZF1 deletion was present in 16 of the 22 patients. The 5-year event-free and overall survival rates were 48.6±9.7% and 73.5±8.6%, respectively. The outcome was not satisfactory without sophisticated minimal residual disease-based stratification. Furthermore, the efficacy of TKIs combined with conventional chemotherapy without allogeneic hematopoietic stem cell transplantation in this cohort should be determined.
doi:10.1038/bcj.2016.28
PMCID: PMC4916297  PMID: 27176795
22.  EMT Involved in Migration of Stem/Progenitor Cells for Pituitary Development and Regeneration 
Epithelial–mesenchymal transition (EMT) and cell migration are important processes in embryonic development of many tissues as well as oncogenesis. The pituitary gland is a master endocrine tissue and recent studies indicate that Sox2-expressing stem/progenitor cells actively migrate and develop this tissue during embryogenesis. Notably, although migration activity of stem/progenitor cells in the postnatal period seems to be reduced compared to that in the embryonic period, it is hypothesized that stem/progenitor cells in the adult pituitary re-migrate from their microenvironment niche to contribute to the regeneration system. Therefore, elucidation of EMT in the pituitary stem/progenitor cells will promote understanding of pituitary development and regeneration, as well as diseases such as pituitary adenoma. In this review, so as to gain more insights into the mechanisms of pituitary development and regeneration, we summarize the EMT in the pituitary by focusing on the migration of pituitary stem/progenitor cells during both embryonic and postnatal organogenesis.
doi:10.3390/jcm5040043
PMCID: PMC4850466  PMID: 27058562
pituitary development; stem/progenitor cell niche; cell regeneration; EMT; migration
23.  Long-chain unsaturated fatty acids reduce the transcriptional activity of the rat follicle-stimulating hormone β-subunit gene 
Here, we assessed the effects of long-chain fatty acids (LCFAs) and the LCFA receptor agonist GW9508 on the transcription of the gonadotropin subunit genes Cga, Lhb and Fshb because LCFA receptor GPR120 was observed in mouse gonadotropes in our recent study. A transcription assay using LβT2 cells demonstrated that LCFAs, oleic acid, α-linolenic acid, docosahexaenoic acid and palmitate, repressed the expression of Cga, Lhb, and Fshb at concentrations between 50 and 100 µM. On the other hand, treatment with 10 µM unsaturated LCFAs, oleic acid, α-linolenic acid and docosahexaenoic acid, repressed only Fshb expression, while the same dose of a saturated LCFA, palmitate, had no effect on the expression of gonadotropin subunit genes. Furthermore, GW9508 did not affect promoter activity. Next, we examined deletion mutants of the upstream region of Fshb and found that the upstream regulatory region (-2824 to -2343 bp) of Fshb was responsible for the notable repression by 10 µM unsaturated LCFAs. Our results suggest that the upstream region of Fshb is susceptible to unsaturated LCFAs. In addition, unsaturated LCFAs play a role in repressing Fshb expression through the distal -2824 to -2343 bp region, which might be independent of the LCFA receptor GPR120 pathway.
doi:10.1262/jrd.2015-138
PMCID: PMC4848577  PMID: 26853521
Follicle-stimulating hormone (FSH); Free fatty acid; Gonadotropin; Luteinizing hormone (LH); Pituitary
24.  Gonadal function, fertility, and reproductive medicine in childhood and adolescent cancer patients: a national survey of Japanese pediatric endocrinologists 
Abstract.
An increasing number of pediatric cancer patients survive, and treatment-related infertility represents one of the most important issues for these patients. While official guidelines in Japan recommend long-term follow-up of childhood cancer survivors (CCSs), their gonadal function and fertility have not been clarified. To address this issue, we organized a working panel to compile evidence from long-term survivors who received treatments for cancer during childhood or adolescence. In collaboration with members of the CCS Committee of the Japanese Society for Pediatric Endocrinology (JSPE), we conducted a questionnaire survey regarding reproductive function in pediatric cancer patients. A cross-sectional survey was sent to 178 JSPE-certified councilors who were asked to self-evaluate the medical examinations they had performed. A total of 151 responses were obtained, revealing that 143 endocrinologists were involved in the care of CCSs. A quarter of the respondents reported having experienced issues during gonadal or reproductive examinations. Several survivors did not remember or fully understand the explanation regarding gonadal damage, and faced physical and psychological distress when discussing the risk of becoming infertile. Pediatric endocrinologists had anxieties regarding their patients’ infertility and the risk of miscarriage, premature birth, and delivery problems. Only a limited number of endocrinologists had experience with managing childbirth and fertility preservation. Many councilors mentioned the necessity for inter-disciplinary communication among healthcare providers. Both endocrinologists and oncologists should set and follow a uniform clinical guideline that includes management of fertility of CCSs.
doi:10.1297/cpe.25.45
PMCID: PMC4860515  PMID: 27212796
childhood cancer survivor; adolescent; pediatric endocrinologist; questionnaire survey; fertility
25.  Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology 
ESMO Open  2016;1(2):e000037.
Diagnosis and treatment of bone metastasis requires various types of measures, specialists and caregivers. To provide better diagnosis and treatment, a multidisciplinary team approach is required. The members of this multidisciplinary team include doctors of primary cancers, radiologists, pathologists, orthopaedists, radiotherapists, clinical oncologists, palliative caregivers, rehabilitation doctors, dentists, nurses, pharmacists, physical therapists, occupational therapists, medical social workers, etc. Medical evidence was extracted from published articles describing meta-analyses or randomised controlled trials concerning patients with bone metastases mainly from 2003 to 2013, and a guideline was developed according to the Medical Information Network Distribution Service Handbook for Clinical Practice Guideline Development 2014. Multidisciplinary team meetings are helpful in diagnosis and treatment. Clinical benefits such as physical or psychological palliation obtained using the multidisciplinary team approaches are apparent. We established a guideline describing each specialty field, to improve understanding of the different fields among the specialists, who can further provide appropriate treatment, and to improve patients’ outcomes.
doi:10.1136/esmoopen-2016-000037
PMCID: PMC5070259  PMID: 27843593
bone metastasis; multidisciplinary team approach; a diagnosis and treatment guideline

Results 1-25 (4874)